BBA
RARX

Baker Bros. Advisors’s Ra Pharmaceuticals, Inc. Common Stock RARX Stock Holding History

Baker Bros. Advisors’s Portfolio RARX Stock Details RARX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-2,093,839
Closed -$101M – 123
2020
Q1 		$101M Hold
2,093,839
– – 0.62% 17
2019
Q4 		$98.3M Sell
2,093,839
-251,657
-11% -$11.1M 0.52% 20
2019
Q3 		$55.5M Buy
2,345,496
+543,801
+30% +$16.1M 0.38% 22
2019
Q2 		$54.2M Buy
1,801,695
+978,582
+119% +$22.4M 0.37% 29
2019
Q1 		$18.4M Hold
823,113
– – 0.12% 37
2018
Q4 		$15M Buy
823,113
+645,161
+363% +$10.1M 0.12% 42
2018
Q3 		$3.22M Hold
177,952
– – 0.02% 82
2018
Q2 		$1.77M Hold
177,952
– – 0.01% 96
2018
Q1 		$945K Hold
177,952
– – 0.01% 102
2017
Q4 		$1.51M Hold
177,952
– – 0.01% 101
2017
Q3 		$2.6M Hold
177,952
– – 0.02% 91
2017
Q2 		$3.33M Hold
177,952
– – 0.03% 73
2017
Q1 		$3.79M Hold
177,952
– – 0.03% 73
2016
Q4 		$2.7M Buy
+177,952
New +$2.42M 0.03% 82

Other funds holding RARX

Daiwa Securities Group
Daiwa Securities Group Tokyo, Japan $34.8B AUM 20.7% 1-Year Est. Return

Baker Bros. Advisors's RARX Position: Q2 2020 in Review

Baker Bros. Advisors sold out of Ra Pharmaceuticals, Inc. Common Stock (RARX) in Q2 2020, closing a stake of 2,093,839 shares — an estimated $101M sold.

Baker Bros. Advisors first reported a position in RARX in Q4 2016 and held it in 14 quarters. The position peaked at $101M in Q1 2020. 1 fund tracked by Wall St. Rank holds RARX as of Q2 2020.

  • Baker Bros. Advisors reported no remaining Ra Pharmaceuticals, Inc. Common Stock position as of Q2 2020 after selling out during the quarter.
  • Baker Bros. Advisors sold 2,093,839 Ra Pharmaceuticals, Inc. Common Stock shares in Q2 2020, an estimated $101M.
  • Baker Bros. Advisors first reported a position in Ra Pharmaceuticals, Inc. Common Stock in Q4 2016 and held it in 14 quarters.
  • Baker Bros. Advisors's Ra Pharmaceuticals, Inc. Common Stock position peaked at $101M in Q1 2020.
  • 1 fund tracked by Wall St. Rank held Ra Pharmaceuticals, Inc. Common Stock as of Q2 2020.

Based on Baker Bros. Advisors's 13F filing for Q2 2020, filed 14 Aug 2020.